<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALPRAZOLAM</span><br/>(al-pray'zoe-lam)<br/><span class="topboxtradename">Niravam, </span><span class="topboxtradename">Xanax, </span><span class="topboxtradename">Xanax XR<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">benzodiazepine</span><br/><b>Prototype: </b>Lorazepam<br/><b>Pregnancy Category: </b>D<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.25 mg, 0.5 mg, 1 mg, 2 mg tablets; 0.5 mg, 1 mg, 2 mg, 3 mg sustained-release tabs; 0.5 mg/5 mL, 1 mg/mL oral solution; 0.25 mg, 0.5 mg, 1 mg, 2 mg orally disintegrating tabs</p>
<h1><a name="action">Actions</a></h1>
<p>CNS depressant. Mode of action not known, but appears to act at the limbic, thalamic, and hypothalamic levels of the CNS.
         It is associated with significantly less drowsiness.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Drug has antidepressant as well as antianxiety actions.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of anxiety disorders or for short-term relief of anxiety symptoms. Also used as adjunct in management of anxiety
         associated with depression and agitation, and for panic disorders, such as agoraphobia.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Alcohol withdrawal.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity to benzodiazepines; acute narrow angle glaucoma; pulmonary disease; use alone in primary depression or psychotic
         disorders; during pregnancy (category D), lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired hepatic function; history of alcoholism; geriatric and debilitated patients. Effectiveness for long-term treatment
         (&gt;4 mo) not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Anxiety Disorders</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.250.5 mg t.i.d. (max: 4 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 0.1250.25 mg b.i.d.<br/><br/><span class="indicationtitle">Panic Attacks</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12 mg t.i.d. (max: 8 mg/d); sustained release: initiate with 0.5 mg to 1 mg once/d. Depending on the response, the dose
               may be increased at intervals of 3 to 4 days in increments of no more than 1 mg/d. Target range 36 mg/d (max: 10 mg/d).<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Reduce dose by 50% in hepatic impairment.<br/> <br/>Do not discontinue abruptly.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Reduce drug gradually when discontinuing drug.</li>
<li>Store in light-resistant containers at 15°30° C (59°86° F), unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness, sedation,</span> light-headedness, dizziness, syncope, depression, headache, confusion, insomnia, nervousness, fatigue, clumsiness, unsteadiness,
      rigidity, tremor, restlessness, paradoxical excitement, hallucinations. <span class="typehead">CV:</span> Tachycardia, hypotension, ECG changes. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">Respiratory:</span> Dyspnea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b> Alcohol</b> and other <span class="classification">cns depressants</span>, <span class="classification">anticonvulsants</span>, <span class="classification">antihistamines</span>, <span class="classification">barbiturates</span>, <span class="classification">narcotic analgesics</span>, <span class="classification">benzodiazepines,</span> compound CNS depressant effects; <b>cimetidine,</b>
<b>disulfiram</b>, <b>fluoxetine</b>, [<span class="classification">tricyclic antidepressants</span>] increase alprazolam levels (decreased metabolism); <span class="classification">oral contraceptives</span> may increase or decrease alprazolam effects. <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation; <b>St. John's wort</b> decreases serum level of alprazolam. Cigarette smoking may decrease serum level of alprazolam by 50%. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Oxidized in liver to inactive metabolites. <span class="typehead">Elimination:</span> Renal elimination. <span class="typehead">Half-Life:</span> 1215 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of drowsiness and sedation, especially in older adults or the debilitated; they may require supervised ambulation
            and/or side rails.
         </li>
<li>Lab tests: Monitor periodic blood counts, urinalyses, and blood chemistry studies, particularly during continuing therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Adverse reactions that may occur during early high-dose therapy. These usually disappear with continuing therapy, but dosage
            adjustments may be indicated.
            						
         </li>
<li>Make position changes slowly and in stages to prevent dizziness.</li>
<li>Do not use alcohol, other CNS depressants, or OTC medications containing antihistamines (e.g., sleep aids, cold, hay fever,
            or allergy remedies) without consulting physician.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Taper dosage following continuous use; abrupt discontinuation of drug may cause withdrawal symptoms: nausea, vomiting, abdominal
            and muscle cramps, sweating, confusion, tremors, convulsions.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>